EDIT
Price
$11.05
Change
+$0.28 (+2.60%)
Updated
Dec 4, 6:59 PM EST
79 days until earnings call
MCRB
Price
$1.14
Change
+$0.07 (+6.54%)
Updated
Dec 4, 6:59 PM EST
92 days until earnings call
Ad is loading...

Compare trend and price EDIT vs MCRB

Header iconEDIT vs MCRB Comparison
Open Charts EDIT vs MCRBBanner chart's image
Editas Medicine
Price$11.05
Change+$0.28 (+2.60%)
Volume$930.03K
CapitalizationN/A
Seres Therapeutics
Price$1.14
Change+$0.07 (+6.54%)
Volume$1.5M
CapitalizationN/A
View a ticker or compare two or three
EDIT vs MCRB Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
EDIT vs. MCRB commentary
Dec 05, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Buy and MCRB is a StrongBuy.

COMPARISON
Comparison
Dec 05, 2023
Stock price -- (EDIT: $11.05 vs. MCRB: $1.12)
Brand notoriety: EDIT and MCRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 93% vs. MCRB: 60%
Market capitalization -- EDIT: $870.23M vs. MCRB: $149.94M
EDIT [@Biotechnology] is valued at $870.23M. MCRB’s [@Biotechnology] market capitalization is $149.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileMCRB’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • MCRB’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than MCRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 5 TA indicator(s) are bullish while MCRB’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 5 bullish, 4 bearish.
  • MCRB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both EDIT and MCRB are a good buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а +3.71% price change this week, while MCRB (@Biotechnology) price change was -3.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.40%. For the same industry, the average monthly price growth was +26.79%, and the average quarterly price growth was +25.75%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 22, 2024.

MCRB is expected to report earnings on Mar 06, 2024.

Industries' Descriptions

@Biotechnology (+5.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for MCRB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EDIT($870M) has a higher market cap than MCRB($150M). EDIT YTD gains are higher at: 24.577 vs. MCRB (-80.000). MCRB has higher annual earnings (EBITDA): -124.01M vs. EDIT (-202.49M). EDIT has more cash in the bank: 350M vs. MCRB (170M). EDIT has less debt than MCRB: EDIT (34.6M) vs MCRB (212M). MCRB has higher revenues than EDIT: MCRB (127M) vs EDIT (24.6M).
EDITMCRBEDIT / MCRB
Capitalization870M150M580%
EBITDA-202.49M-124.01M163%
Gain YTD24.577-80.000-31%
P/E RatioN/AN/A-
Revenue24.6M127M19%
Total Cash350M170M206%
Total Debt34.6M212M16%
FUNDAMENTALS RATINGS
EDIT vs MCRB: Fundamental Ratings
EDIT
MCRB
OUTLOOK RATING
1..100
1820
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3797
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (45) in the Biotechnology industry is in the same range as MCRB (66). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MCRB (100). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as MCRB (100). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

EDIT's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for MCRB (97). This means that EDIT’s stock grew somewhat faster than MCRB’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MCRB (100). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITMCRB
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCVTX17.350.20
+1.17%
Fidelity Advisor® Small Cap Value M
DISSX25.89N/A
N/A
BNY Mellon Small Cap Stock Index Inv
PJDAX16.22N/A
N/A
PGIM Jennison Rising Dividend A
BSUIX9.32N/A
N/A
BlackRock Sustainable Intntl Eq Ins
DTCAX15.59N/A
N/A
BNY Mellon Sust US Equity A

MCRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with MDGL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
+4.67%
MDGL - MCRB
48%
Loosely correlated
+4.16%
AGIO - MCRB
42%
Loosely correlated
+0.70%
ORMP - MCRB
42%
Loosely correlated
+0.47%
NRIX - MCRB
39%
Loosely correlated
+8.83%
AXON - MCRB
38%
Loosely correlated
+2.09%
More